EZH2 and breast cancer: Furthermore, dual-target inhibitors toward both EZH2 and EHMT2 are being developed, including HKMTI-1-005, HKMTI-1-022, and HKMTI-1-011, which are more effective at re-expressing aberrantly silenced genes and BC cell growth compared to single target inhibitors (Curry et al., 2015).